glp-1 vision changes drugs are associated with a 35% higher risk of NAION, an eye condition that can cause sudden loss. About 6 to 10 extra cases per 10,000 users over 3 years GLP 1 Blindness Risk |

Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency

Barber, T

If IBS-D worsens, your clinician can explore tirzepatide, oral formulations, or the Microdose Protocol

For most people, missing one dose does not immediately undo previous progress

Collectively, the progression from exenatide to tirzepatide illustrates how extending the half-life of GLP-1R agents and incorporating additional mechanisms of action has led to substantial improvements in both glycemic control and weight loss

Researchers believe that more than half of all women will experience a UTI at some point in their life